Transcend Capital Advisors LLC Has $642,000 Position in Gilead Sciences, Inc. $GILD

Transcend Capital Advisors LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,788 shares of the biopharmaceutical company’s stock after purchasing an additional 318 shares during the period. Transcend Capital Advisors LLC’s holdings in Gilead Sciences were worth $642,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC increased its stake in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 2,450 shares during the period. Bison Wealth LLC bought a new position in Gilead Sciences during the 4th quarter worth $215,000. Golden State Wealth Management LLC increased its stake in Gilead Sciences by 14.5% during the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company’s stock worth $97,000 after acquiring an additional 109 shares during the period. Essex Financial Services Inc. increased its stake in Gilead Sciences by 2.6% during the 1st quarter. Essex Financial Services Inc. now owns 6,060 shares of the biopharmaceutical company’s stock worth $679,000 after acquiring an additional 153 shares during the period. Finally, Koshinski Asset Management Inc. increased its stake in Gilead Sciences by 23.8% during the 1st quarter. Koshinski Asset Management Inc. now owns 4,350 shares of the biopharmaceutical company’s stock worth $487,000 after acquiring an additional 836 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on GILD. BMO Capital Markets raised their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a research note on Monday, October 20th. JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. UBS Group raised their price objective on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Royal Bank Of Canada raised their price objective on Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 8th. Finally, TD Cowen lifted their price target on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $122.61.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $354,240.00. Following the sale, the insider owned 110,193 shares of the company’s stock, valued at $13,011,589.44. This trade represents a 2.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the sale, the chief financial officer directly owned 157,055 shares in the company, valued at approximately $18,545,054.40. This trade represents a 1.57% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 61,500 shares of company stock valued at $7,142,140 in the last 90 days. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Trading Down 2.1%

Shares of GILD opened at $117.88 on Wednesday. Gilead Sciences, Inc. has a 52-week low of $86.08 and a 52-week high of $124.61. The business’s fifty day moving average is $115.51 and its 200-day moving average is $111.33. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The firm has a market cap of $146.27 billion, a price-to-earnings ratio of 23.48, a PEG ratio of 0.83 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter last year, the company posted $2.01 EPS. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.